Table 4. Non-inferiority concordance study for clinical validity for the detection of EGFR exon 19 deletions and L858R substitutions in NSCLC (n = 177).

Comparison	PPA	NPA
Ref2|Ref1	95.3%	98.9%
Ref1|Ref2	96.1%	98.7%
CGP|Ref1	97.7%	95.6%
CGP|Ref2	97.7%	95.4%

CGP = FoundationOne Liquid CDx; NPA = negative percent agreement; PPA = positive percent agreement; Ref1 = reference assay replicate 1; Ref2 = reference assay replicate 2.